Work

Supplementary Figure 1 from Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 66KB, OP449 in combination with ABL1 tyrosine kinase inhibitors inhibits BCR-ABL1 signaling in CML cells and cellular growth of primary CML blastic phase cells ex vivo.

DOI: 10.1158/1078-0432.22449390.v1

Authors: Anupriya Agarwal, Ryan J. MacKenzie, Raffaella Pippa, Christopher A. Eide, Jessica Oddo, Jeffrey W. Tyner, Rosalie Sears, Michael P. Vitek, María D. Odero, Dale J. Christensen, Brian J. Druker

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361818843

Cites:

Cited by:

Related to: 10